Estrogen induction and contact phase activation of human factor XII

Steroids

Volumn 61, Issue 4, 1996, Pages 270-276

  Citarella, Franca ^a   Misiti, Silvia ^a   Felici, Angelina ^a   Farsetti, Antonella ^b   Pontecorvi, Alfredo ^c   Fantoni, Antonio ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

contact phase; estrogen; factor XII; fibrinolysis; promoter

Indexed keywords

BLOOD CLOTTING FACTOR 12;

AMINO TERMINAL SEQUENCE; BLOOD CLOTTING; CONFERENCE PAPER; FIBRINOLYSIS; HEMOSTASIS; HORMONE RESPONSIVE ELEMENT; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN DOMAIN; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EUKARYOTA; VACCINIA; VACCINIA VIRUS;

EID: 0029916576     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0039-128X(96)00037-2     Document Type: Conference Paper

References (77)

1. Kaplan AP, Silverberg M (1987). The coagulation-kinin pathway of human plasma. Blood 70:115-127.
2. Wiggins RC, Bouma BN, Cochrane CG, Griffin JH (1977). Role of the high molecular weight kininogen in surface-binding and activation of coagulation Factor XI and prekallikrein. Proc Natl Acad USA 74:4636-4640.
3. Colman RW (1984). Surface mediated defense reactions. The plasma contact activation system. J Clin Invest 73:1249-1253.
4. Citarella F, Tripodi M, Fantoni A, Bernardi F, Patracchini P, Romeo G, Rocchi M (1988). Hum Genet 80:397-398.
5. Royle NJ, Nigli M, Cool D, MacGillivray RT, Hamerton JL (1988). Structural gene encoding human factor XII is located at 5q33-ter. Cell Mol Genet 12:217-221.
6. Cool DE, MacGillivray RTA (1987). Characterization of the human blood coagulation Factor XII gene. J Biol Chem 262:13662-13673.
7. Cool DE, Edgell CS, Louie GV, Zoller MJ, Brayert GD, MacGillivray RTA (1985). Characterization of human blood coagulation Factor XII cDNA. J Biol Chem 260:1366-1376.
8. Tripodi M, Citarella F, Guida S, Galeffi P, Fantoni A, Cortese R (1986). cDNA sequence coding for human coagulation Factor XII. Nucleic Acids Res 14:3146.
9. Tans G, Rosing J (1987). Structural and functional characterization of Factor XII. Semin Thromb Hemostasis 13:1-14.
10. Pixley RA, Colman RW (1993). Factor XII: Hageman Factor. In: Lorand L, Mann KG (eds), Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation, Academic Press, San Diego, pp. 51-65.
11. Hack CE, Dors D (1992). Activation and inhibition of Factor XII (Hageman Factor) in vivo. Curr Opin Invest Drugs Nov/Dec 95-110.
12. Cochrane CG, Revak SD, Wuepper KD (1973). Activation of Hageman Factor in solid and fluid phases. J Exp Med 138:1564-1583.
13. Griffin JH (1978). Role of surface in surface-dependent activation of Hageman Factor (blood coagulation Factor XII). Proc Natl Acad Sci USA 75:1998-2002.
14. Samuel M, Pixley RA, Villanueva MA, Colman RW, Villanueva GB (1992). Human Factor XII (Hageman Factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies. J Biol Chem 267:19691-19697.
15. Revak SD, Cochrane CG, Johnson AR, Hugh TH (1974). Structural changes accompanying enzymatic activation of human Hageman Factor. J Clin Invest 54:619-627.
16. Dunn JR, Silverberg M, Kaplan AP (1982). The cleavage and formation of activated human Hageman Factor by autodigestion and by kallikrein. J Biol Chem 257:1779-1784.
17. Tankersley DL, Finlayson JS (1984). Kinetics of activation and autoactivation of human Factor XII. Biochemistry 23:273-279.
18. Naito K, Fujikawa K (1991). Activation of human blood coagulation Factor X independent of Factor XII. J Biol Chem 266:7353-7358.
19. Scott FC, Colman RW (1992). Fibrinogen blocks the autoactivation and thrombin medicated activation of factor IX on dextron sulfate. Proz Natl Acad Sci 89:11189-11193.
20. Furie B, Furie BC (1988). The molecular basis of blood coagulation. Cell 53:505-518.
21. Smith D, Gilbert M, Owen WG (1985). Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66: 835-839.
22. Berrettini M, Schleef RR, Espana F, Loskutoff DJ, Griffin JH (1989). Interaction of type I plasminogen inhibitor with the enzymes of the contact activation system. J Biol Chem 264:11738-11743.
23. Ratnoff OD (1991). The hormonal control of the synthesis of Hageman Factor (Factor XII). J Lab Clin Med 117:343-551.
24. Von-Kanel R, Wuillemin WA, Furlan M, Lammle B (1992). Factor XII clotting activity and antigen levels in patients with thromboembolic disease. Blood Coagulation Fibrinol 3:555-561.
25. Inman WHW, Vessey MP, Westerholm B, Engelund A (1970). Thromboembolic disease and the steroidal content of oral contraceptives. A report to the committee on safety of drugs. Br Med J 2:203-209.
26. Gordon EM, Ratnoff OD, Saito H, Donaldson VH, Pensky J, Jones PK (1980). Rapid fibrinolysis, augmented Hageman Factor (Factor XII) and decreased Cl esterase inhibitor titers in women taking oral contraceptives. J Lab Clin Med 96:762-769.
27. Kobayashi N, Takeda Y (1977). Effects of a large dose of estradiol on antithrombin III metabolism in male and female dogs. Eur J Clin Invest 7:373-381.
28. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991). Postmenopausal estrogen therapy and cardiovascular disease. Ten years follow up from the nurses' health study. N Engl J Med 325:756-762.
29. Devor M, Barrett-Connor E, Renvall M, Feigal D Jr, Ramsdell J (1992). Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 92:275-282.
30. Collins P, Rosano GM, Jang C, Lindsay D, Sarrel PM, Poole-Wilson PA (1993). Cardiovascular protection by estrogen. A calcium antagonist effect? Lancet 341:1264-1265.
31. Manolio TA, Furberg CD, Shemanski L, Psaty BM, O'Leary DH, Tracy RP, Bush TL (1993). Association of post-menopausal estrogen use with cardiovascular disease and its risk factors in older women. Circulation 88:2163-2171.
32. Bottiger LE, Boman G, Eklund G, Westerholm B (1980). Oral contraceptives and thromboembolic disease: effect of lowering oestrogen content. Lancet 315:1097-1101.
33. Notelovitz M, Kichens C, Ware MD, Hirschberg K, Coone L (1983). Combination estrogen and proestrogen replacement therapy does not adversely affect coagulation. Obstet Gynecol 62:596-600.
34. Lobo RA (1992). Estrogen and risk of coagulopathy. Am J Med 92:283-285.
35. Notelovitz M, Kitchens C, Rapport V, Coone L, Dougherty M (1981). Menopausal status associated with increased inhibition of blood? Am J Obstet Gynecol 141:149-152.
36. Barrett-Connor E, Brown WV, Turner J, Austin M, Criqui MH (1979). Heart disease risk factors and hormone use in postmenopausal women. JAMA 241:2167-2169.
37. Bourne T, Hillard TC, Whitehead MI, Crook D, Campbell S (1990). Oestrogens, arterial status and postmenopausal women. Lancet 335: 1470-1471.
38. Lobo RA (1991). Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 73:925-930.
39. Gordon EM, Williams SR, Frencheck B, Mazur CA, Speroff L (1988). Dose dependent effects of postmenopausal oestrogen and progestin on antithrombin III and Factor XII. J Lab Clin Med 111: 52-56.
40. Jespersen J, Kluft C (1985). Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen: levels of extrinsic and intrinsic plasminogen activators, prekallikrein, Factor XII and Cl inactivator. Thromb Haemostasis 54:454-459.
41. Gordon EM, Johnson TR, Ramos LP, Schmeider-Sapiro KT (1991). Enhanced expression of Factor XII (Hageman Factor) in isolated livers of estrogen- and prolactin-treated rats. J Lab Clin Med 117: 353-358.
42. Gordon EM, Douglas JG, Ratnoff OD, Arafah BUM (1985). The influence of estrogen and prolactin on Hageman Factor (Factor XII) titer in ovariectomized and hypophysectomized rat. Blood 66:602-605.
43. Citarella F, Aiuti A, Misiti S, Felici A, La Porta C, Fantoni A (1993). The 5′ sequence of human Factor XII gene contains transcription regulatory elements typical of liver specific, estrogenmodulated genes. Biochim Biophys Acta 1172:197-199.
44. Salier JP, Hirosawa S, Kurachi K (1990). Functional characterization of the 5' regulatory region of human factor IX gene. J Biol Chem 265:7062-7068.
45. Ramji DP, Tadros MN, Hardon EM, Cortese R (1991). The tran scription factor LF-A1 interacts with a bapartite recognition sequence in the promoter regions of several liver-specific genes. Nucleic Acids Res 19:1139-1146.
46. Evans RM (1988). The steroid and tyzoid hormone receptor super family. Science 240:889-895.
47. Farsetti A, Misiti S, Citarella F, Felici A, Andreoli M, Fantoni A, Sacchi A, Pontecorvi A (1995). Molecular basis of estrogen regulation of Hageman Factor XII gene expression. Endocrinology 136: 5076-5083.
48. Medici N, Nigro V, Abbondanza C, Moncharmont B, Molinari AM, Puca GA (1991). In vitro binding of the purified hormone-binding subunit of the estrogen receptor to oligonucleotides containing natural or modified sequences of an estrogen responsive element. Mol Endocrinol 5:555-563.
49. Kato S, Tora L, Yamauchi J, Masushigo S, Bellard M, Chambon P (1992). A far upstream estrogen response element of the ovalbumin gene contains several half-palindromic 5′ TGACC 3′ motifs acting synergistically. Cell 68:731-742.
50. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M (1994). Estrogen receptor-associated proteins: possible mediators of hormone induced transcription. Science 264:1455-1458.
51. Cavailles V, Dauvois S, Danielian PS, Parker MG (1994). Interaction of proteins with transcriptionally active estrogen receptor. Proc Natl Acad Sci USA 91:10009-10013.
52. Martinez E, Givel F, Wahli W (1987). The estrogen responsive element as an inducible enhancer: DNA sequence requirements and conversion to a glucocorticoid-responsive element. EMBO J 6: 3719-3727.
53. Naar AM, Boutin JM, Lipkin SM, Yu VC, Holloway JM, Glass CK, Rosenfeld MG (1991). The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors. Cell 65:1267-1279.
54. Mader S, Kumar V, De Verneuil H, Chambon P (1989). Three amino acids of the oestrogen receptor are essential to its ability to distinguish an oestrogen from a glucocorticoid-responsive element. Nature 338:271-274.
55. Glass CK, Holloway JM, Devary OV, Rosenfeld MG (1988). The thyroid hormone receptors binds with opposite transcriptional effects to a common sequence motif in thyroid hormone and estrogen response elements. Cell 54:313-323.
56. Berry M, Nunez AM, Chambon P (1989). Estrogen responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86:1218-1222.
57. Slater EP, Redeuhil G, Theis K, Suske, Beato M (1990). The utero globin promoter contains a non-canonical estrogen responsive element. Mol Endocrinol 4:604-610.
58. Truss M, Beato M (1993). Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 14:459-479.
59. Crossley M, Ludwig M, Stowell KM, De Vos P, Olek K, Brownlee GG (1992). Recovery from haemophilia B Leyden: an androgen responsive element in the Factor IX promoter. Science 257:377-379.
60. Citarella F, Aiuti A, La Porta C, Russo G, Pietropaolo C, Rinaldi M, and Fantoni A (1992). Control of human coagulation by recombinant serine proteases. Eur J Biochem 208:23-30.
61. Cochrane CG, Griffin JH (1982). The biochemistry and pathophysiology of the contact system of plasma. Adv Immunol 33:241-304.
62. Griffin JH, Bouma BN (1987). The contact phase of blood coagulation. In: Bloom AL, Thomas DP (eds), Haemostasis and Thrombosis, Churchill Livingstone, Edinburgh, pp. 101-115.
63. Silverberg M, Dunn JT, Garen L, Kaplan AP (1980). Autoactivation of human Hageman Factor: demonstration utilizing a synthetic substrate. J Biol Chem 255:7281-7286.
64. Dunn JT, Silverberg M, Kaplan AP (1982). The cleavage and formation of activated human Hageman Factor by autodigestion and by kallikrein. J Biol Chem 257:1779-1784.
65. Espana F, Ratnoff OD (1983). Activation of Hageman Factor by sulfatides and other agents in the absence of plasma proteases. J Lab Clin Med 102:31-45.
66. Tans G, Rosing J, Griffin JH (1983). Sulfatide-dependent autoactivation of human blood coagulation Factor XII (Hageman Factor). J Biol Chem 258:8215-8222.
67. Tans G, Rosing J (1987). Structural and functional characterization of Factor XII. Semin Thromb Hemostasis 13:1-14.
68. Rosing J, Tans G, Griffin JH (1985). Surface-dependent activation of human Factor XII (Hageman Factor) by kallikrein and its light chain. Eur J Biochem 151:531-538.
69. Tans G, Rosing J, Berrettini M, Lammle B, Griffin JH (1987). Autoactivation of human plasma prekallikrein. J Biol Chem 262: 11308-11314.
70. Tans G, Griffin JH (1982). Properties of sulfatides in Factor-XII-dependent contact activation. Blood 59:69-75.
71. Revak SD, Cochrane CG (1976). The relationship of structure and function in human Hageman Factor. The association of the enzymatic and binding activities with separate regions of the molecule. J Clin Invest 57:852-860.
72. Revak SD, Cochrane CG, Bouma BN, Griffin JH (1978). Surface and fluid phase activities of two forms of activated Hageman Factor produced during contact activation of plasma. J Exp Med 147:719-729.
73. Reddigari SR, Shibayama Y, Buraée T, Kaplan AP (1993). Human Hageman Factor (Factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. J Biol Chem 286:11982-11987.
74. Pixley RA, Colman RW (1993). Factor XII: Hageman Factor. In: Lorand L, Mann KG (eds), Proteolytic Enzymes in Coagulation, Fibrinolysis, and Complement Activation, Academic Press, San Diego, pp. 51-65.
75. Clarke BJ, Côté HCF, Cool DE, Clark-Lewis I, Saito H, Pixley LA (1989). Mapping of a putative surface-binding site of human coagulation Factor XII. J Biol Chem 264:11497-11502.
76. Samuel E, Samuel M, Villanueva GB (1993). Histidine residues are essential for the surface binding and autoactivation of human coagulation factor XII. Biochem Biophys Res Commun 191:110-117.
77. Pixley RA, Stumpo LG, Birkmeyer K, Silver L, Colman RW (1987). A monoclonal antibody recognizing an ioosapeptide sequence in the heavy chain of human Factor XII inhibits surface-catalyzed activation. J Biol Chem 262:10140-10145.